View Older Stories View More Recent Stories

Feb 1, 2021 06:47AM Merck (MRK) Reports Election of Dr. Stephen Mayo to Board
Feb 1, 2021 06:45AM Dr. Stephen Mayo Elected to Merck Board of Directors
Feb 1, 2021 06:37AM Merck (MRK) Announces Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA (pembrolizumab) in Certain Patients with R/R Classical Hodgkin Lymphoma
Feb 1, 2021 06:30AM Merck (MRK) Reports Results from Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab (Yervoy)
Feb 1, 2021 06:30AM Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA® (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Jan 29, 2021 07:23PM Merck Presents Results From Head-to-Head Phase 3 KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic
Jan 27, 2021 08:00AM Merck Announces Second Cohort of Safer Childbirth Cities Organizations Committed to Improving Maternal Health Equity and Reducing Preventable Maternal Deaths in the US
Jan 26, 2021 01:15PM Merck Announces Second-Quarter 2021 Dividend
Jan 26, 2021 09:06AM Merck (MRK) Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021
Jan 26, 2021 09:06AM Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021
Jan 26, 2021 06:47AM Merck (MRK) Reports EC Approves KEYTRUDA (pembrolizumab) as First-Line Treatment in Adult Patients with MSI-H or dMMR Colorectal Cancer
Jan 26, 2021 06:45AM European Commission Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal
Jan 25, 2021 06:45AM Merck (MRK) Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates
Jan 25, 2021 06:45AM Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates
Jan 25, 2021 02:00AM European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Jan 20, 2021 06:49AM Merck (MRK) Announces U.S. FDA Approval of VERQUVO
Jan 20, 2021 06:45AM Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat)
Jan 12, 2021 06:48AM Merck (MRK) Announces FDA Accepts for Priority Review the BLA for V114, its Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older
Jan 12, 2021 06:45AM U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older
Jan 8, 2021 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference Call on February 4
Jan 7, 2021 04:00AM MilliporeSigma Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics
Jan 4, 2021 06:45AM Merck to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 28, 2020 06:47AM AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA Granted Three New Approvals in Japan
Dec 28, 2020 06:45AM LYNPARZA® (olaparib) Receives Three New Approvals in Japan
Dec 23, 2020 06:46AM Merck (MRK) Announces Supply Agreement with U.S. Government for Initial Doses of Investigational Biological Therapy for Treatment of Patients with Severe and Critical COVID-19
Dec 23, 2020 06:45AM Merck Announces Supply Agreement with U.S. Government for Initial Doses of Investigational Biological Therapy for the Treatment of Patients with Severe and Critical COVID-19
Dec 17, 2020 06:47AM Merck (MRK) Announces FDA Grants Priority Review to its sBLA for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Esophageal and Gastroesophageal Junc
Dec 17, 2020 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metasta
Dec 16, 2020 06:47AM Merck (MRK) Announces KEYTRUDA Plus LENVIMA Demonstrated Statistically Significant Improvement in OS, PFS and ORR Vs Chemo in Patients With Advanced Endometrial Cancer
Dec 16, 2020 06:45AM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus
Dec 11, 2020 08:00AM BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Dec 11, 2020 07:11AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer
Dec 11, 2020 07:10AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (d
Dec 7, 2020 08:00AM MilliporeSigma Expands Production Capacities
Nov 30, 2020 06:45AM Merck to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual Conference
Nov 23, 2020 09:06AM Merck Animal Health Survey Reveals First-Time Dog Owners Need Support
Nov 23, 2020 06:48AM Merck (MRK) Submits Applications for Licensure of V114, the Company’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and EMA
Nov 23, 2020 06:47AM Merck Submits Applications for Licensure of V114, the Company’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines Agency
Nov 23, 2020 06:45AM Merck (MRK) to Acquire OncoImmune for $425 Million
Nov 23, 2020 06:45AM Merck to Acquire OncoImmune
Nov 17, 2020 01:25PM Merck Announces First-Quarter 2021 Dividend
Nov 16, 2020 06:46AM Merck (MRK) Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
Nov 16, 2020 06:45AM Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
Nov 13, 2020 04:11PM FDA Approves Merck’s (MRK) KEYTRUDA in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 (CPS ≥10)
Nov 13, 2020 04:10PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express P
Nov 10, 2020 06:49AM Merck (MRK) Announces KEYTRUDA Plus LENVIMA Demonstrated Statistically Significant Improvement in PFS, OS and ORR Versus Sunitinib as First-Line Treatment for Patients with RCC
Nov 10, 2020 06:45AM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Ve
Nov 9, 2020 04:58PM Merck (MRK) Announces KEYNOTE-598 Trial Evaluating KEYTRUDA in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic NSCLC To Stop for Futility
Nov 9, 2020 04:10PM Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Sto
Nov 5, 2020 06:45AM LYNPARZA® (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer
View More Recent Stories View Older Stories